Key terms
About ORGS
Orgenesis, Inc. is a biotechnology company, which engages in the development, manufacturing, and provision of technologies, and services in the cell and gene therapy industry. It operates through the Morgenesis and Therapies segments. The Morgenesis segment refers to the POCare services. The Therapies segment is involved in therapeutic development operations. The company was founded by Sarah Ferber on June 5, 2008 and is headquartered in Germantown, MD.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ORGS news
Apr 22
1:29pm ET
Orgenesis files $100M mixed securities shelf
Mar 13
8:46am ET
Orgenesis awarded EUR 1.5M grant from Walloon Government
Mar 04
8:42am ET
Orgenesis to sell 2.27M shares at $1.03 in private placement
Feb 29
8:43am ET
Orgenesis awarded EUR 2M grant from Walloon Government in Belgium
Jan 31
9:17am ET
Orgenesis to acquire 25% stake in Octomera from MM OS Holdings
Jan 25
4:28am ET
Orgenesis Inc. Secures Acquisition of Octomera LLC
No recent press releases are available for ORGS
ORGS Financials
Key terms
Ad Feedback
ORGS Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ORGS Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range